Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
Authors:
Open Access
- 19 May 2022
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 41, 16-23
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Phase‐1 study of abiraterone acetate in chemotherapy‐naïve Japanese patients with castration‐resistant prostate cancerCancer Science, 2014
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trialsInternational Journal of Clinical Oncology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaCancer, 2002
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000